<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02253836</url>
  </required_header>
  <id_info>
    <org_study_id>1182.61</org_study_id>
    <nct_id>NCT02253836</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir</brief_title>
  <official_title>A Single-Centre Open-Label Study in Healthy Adult Volunteers to Assess the Pharmacokinetic Interactions Between Steady-State TPV (500 mg) and Single-Dose and Steady-State Atazanavir (300 mg QD) in the Presence of Ritonavir (100 mg)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate the effects of steady-state TPV/r (500 mg/100 mg BID) on the single-dose
      and steady-state pharmacokinetics of Atazanavir (300 mg QD) co-administered with Ritonavir
      (100 mg). To investigate the effects of single-dose and steady-state Atazanavir (300 mg) on
      the steady-state pharmacokinetics of Tipranavir and Ritonavir.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration</measure>
    <time_frame>up to day 33</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug concentration in plasma at 12 hr after administration for Tipranavir (TPV) and Ritonavir (RTV)</measure>
    <time_frame>12 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug concentration in plasma at 24 hr after administration for Atazanavir (TAZ)</measure>
    <time_frame>24 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under plasma concentration time curve from 0-12 hours (AUC0-12h) for TPV and RTV</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24h for TAZ</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum concentration</measure>
    <time_frame>up to day 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life</measure>
    <time_frame>up to day 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral clearance</measure>
    <time_frame>up to day 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>up to day 33</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to day 33</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>TAZ/RTV - TPV/RTV - TPV/RTV+TAZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 1-9: single dose TAZ/RTV
Days 16-23: morning and evening dose TPV/RTV
Days 24-32: TPV/RTV + TAZ</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir</intervention_name>
    <description>TPV</description>
    <arm_group_label>TAZ/RTV - TPV/RTV - TPV/RTV+TAZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>RTV</description>
    <arm_group_label>TAZ/RTV - TPV/RTV - TPV/RTV+TAZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>TAZ</description>
    <arm_group_label>TAZ/RTV - TPV/RTV - TPV/RTV+TAZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects between 18 and 60 years of age inclusive

          2. A Body Mass Index (BMI) between 18 and 29 kg/m2

          3. Signed informed consent prior to trial participation

          4. Ability to swallow multiple large capsules without difficulty

          5. Acceptable laboratory values that indicate adequate baseline organ function at
             screening visit:

               -  Laboratory values are considered to be acceptable if the severity of any
                  parameter is â‰¤ Grade 1, based on the Division of AIDS/AIDS Clinical Trials Group
                  Grading Scale

               -  All abnormal laboratory values &gt; Grade 1 are subject to approval by the trial
                  clinical monitor

          6. Acceptable medical history, physical examination, and 12-lead ECG at screening

          7. Willingness to abstain from the following starting 2 weeks prior to administration of
             any study medication and up until the end of the study:

             - Grapefruit or grapefruit juice, Red wine, Seville oranges, St. John's Wort, and Milk
             Thistle

          8. Willingness to abstain from alcohol starting 3 days prior to administration of any
             study medication up to the end of the study

          9. Willingness to abstain from the following starting 3 days prior to pharmacokinetic
             (PK) sampling:

             - Garlic supplements and Methylxanthine containing foods or drinks (including coffee,
             tea, cola, energy drinks, chocolate, etc.)

         10. Willingness to abstain from over-the-counter herbal medications for the duration of
             the study

         11. Must be a non-smoker

         12. Willingness to abstain from vigorous physical exercise during intensive PK Days 1, 9,
             23, 24 and 32

         13. Reasonable probability for completion of the study

        Exclusion Criteria:

          1. Female subjects of reproductive potential who:

               -  Have positive serum pregnancy test

               -  Have not been using a barrier method of contraception for at least 3 months prior
                  to participation in the study

               -  Are not willing to use a reliable method of barrier contraception (such as
                  diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during
                  and 60 days after completion/termination of the trial

               -  Are breast-feeding

          2. Participation in another trial with an investigational medicine within 2 months prior
             to Day 0 of this study

          3. Use of any medication listed in the protocol within 30 days prior to Day 0 of this
             study

          4. Use of any pharmacological contraceptive (including oral, patch or injectable
             contraceptives) within 1 month prior to Day 0 and for the duration of the study. Due
             to long half-life,subjects using of Depo-Provera within six months prior to Day 0 will
             be excluded from participation in this study

          5. Use of hormone replacement therapy within 1 month prior to Day 0 and anytime during
             the study

          6. Administration of antibiotics within 15 days prior to Day 0 and anytime during the
             study

          7. History of acute illness within 60 days prior to Day 0

             o Subjects will be excluded for acute illnesses that occurred more than 60 days prior
             to Day 0 if, in the opinion of the investigator, the subject does not qualify as a
             healthy volunteer

          8. Have serological evidence of hepatitis B or C virus

          9. Have serological evidence of exposure to HIV

         10. Alcohol or substance abuse within 1 year prior to screening or during the study

         11. Blood or plasma donations within 30 days prior to Day 0 or during the study

         12. Subjects with a history of any illness or allergy that, in the opinion of the
             investigator, might confound the results of the study or pose additional risk in
             administering Tipranavir, Ritonavir or Atazanavir to the subject

         13. Subjects with pre-existing heart conduction abnormalities

         14. Subjects who have taken (within 7 days prior to Day 0) any over-the-counter or
             prescription medication that, in the opinion of the investigator in consultation with
             the clinical monitor, might interfere with absorption, distribution, or metabolism of
             the study medications

         15. Known hypersensitivity to sulphonamide class of drugs

         16. Inability to adhere to the protocol

         17. Cautions or warnings in the Ritonavir and Atazanavir package insert which, in the
             opinion of the investigator, constitute grounds for subject exclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>September 30, 2014</last_update_submitted>
  <last_update_submitted_qc>September 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

